Boston Scientific Corporation $BSX Shares Acquired by Brookstone Capital Management

Brookstone Capital Management lifted its position in Boston Scientific Corporation (NYSE:BSX) by 12.0% in the third quarter, Holdings Channel reports. The firm owned 129,321 shares of the medical equipment provider’s stock after acquiring an additional 13,906 shares during the period. Brookstone Capital Management’s holdings in Boston Scientific were worth $12,626,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after acquiring an additional 2,545,381 shares during the period. State Street Corp raised its position in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Geode Capital Management LLC boosted its stake in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after purchasing an additional 622,602 shares during the period. Norges Bank acquired a new stake in Boston Scientific during the 2nd quarter worth $2,089,937,000. Finally, Invesco Ltd. grew its position in Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after purchasing an additional 226,578 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of several recent research reports. Royal Bank Of Canada increased their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Friday, November 21st. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Cowen restated a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Finally, Leerink Partners lifted their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $124.85.

Insider Activity

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 143,095 shares of company stock worth $14,228,950 in the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Down 0.1%

BSX opened at $96.00 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The stock has a market capitalization of $142.31 billion, a P/E ratio of 51.34, a P/E/G ratio of 1.94 and a beta of 0.67. The business has a 50 day simple moving average of $98.60 and a 200-day simple moving average of $101.10.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the company posted $0.63 earnings per share. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.